Company / PP&E (Net)
Ultragenyx Pharmaceutical Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$244.0M
FY2025
5-year range
$141.2M / $290.6M
FY2021-FY2025
Trend
-8.3%
vs FY2024
Sector context
#28 of 193
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s pp&e (net) of $244M is higher than 85% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $17M in FY2016 to $291M in FY2023.
Based on SEC 10-K filings.
$244M in FY2025 with a 5-year CAGR of +27.1%. Top quartile in the Health Care sector.
Declined from $291M to $244M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -2.1%
- 5-Year CAGR
- +27.1%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 193This company $244.0M Sector average $777.6M
▼
-68.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.1%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 8.3% year-over-year.
- Ranks #28 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $244.0M | -8.3% |
| FY2024 | $266.0M | -8.5% |
| FY2023 | $290.6M | +11.9% |
| FY2022 | $259.7M | +83.9% |
| FY2021 | $141.2M | +92.1% |
| FY2020 | $73.5M | +65.8% |
| FY2019 | $44.3M | +121.2% |
| FY2018 | $20.0M | -8.2% |
| FY2017 | $21.8M | +28.0% |
| FY2016 | $17.1M | +131.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026